Duchenne muscular dystrophy

Other care recommendations

Existing literature

In addition to the new consensus guidelines, where it is possible to obtain permission from the publishers, our aim is to make available the most useful existing published literature on the TREAT-NMD site. A selection of articles are provided below and more will be added as we gain the appropriate permissions.

K Bushby et al. The multidisciplinary management of DMD
In recent years there has been the recognition that there are a number of management interventions that can alter the natural history of Duchenne muscular dystrophy (DMD) so that the majority of people with DMD can be expected to live into adult life.

K Bushby et al. Report on the 124th ENMC International Workshop "Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids"
Thirty-two participants representing parents, funding agencies and clinicians involved in the care of children with Duchenne Muscular Dystrophy (DMD) from Belgium, Canada, Denmark, Finland, France, Germany, Italy, the Netherlands, Spain, Sweden, the UK and the USA met in Naarden on 2-4 April 2004.

TREAT-NMD interim recommendations

 Prior to the launch of the full academic care standards publication, TREAT-NMD assembled a group of experts, primarily co-authors of existing DMD management guidelines, created a set of "interim recommendations", the aim of which was to achieve the rapid dissemination of existing knowledge in this area while awaiting the more detailed recommendations in the full document. These guidelines are to be considered as expert opinion, and are not based on systematic review processes, although an evidence-based approach guided the work. These guidelines have already been translated into several languages and you can download a PDF of these TREAT-NMD care recommendations using the link on the right.

 

 


TREAT-NMD Coordination Office: T: +44 191 241 8605 Fax: +44 191 241 8770 E:
FP6 Logo TREAT-NMD is supported through Priority 1 (Life Sciences, Genomics and Biotechnology for Health) of the European Union’s FP6 under contract number LSHM-CT-2006-036825 EU flag